Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Prices Offering of Senior Notes

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific late on Thursday priced its offering of $800 million of senior notes at 99.991 percent of the principal amount.

The issuance of the notes is expected to close on or about Nov. 14, the company said. Net proceeds will be used primarily to repay debt, including the $400 million principal amount of its 3.25 percent senior notes due 2014 that mature on Nov. 20.

The joint book-running managers for the offering are Merrill Lynch, Pierce, Fenner & Smith; Mitsubishi UFJ Securities; Citigroup Global Markets; and Credit Suisse Securities.

Thermo Fisher announced its plans to offer the dollar-denominated senior notes on Thursday and said that it may also offer euro-denominated senior notes before the end of the year. Fitch Ratings gave the senior notes a BBB rating and said the rating outlook is negative.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.